Welcome to our dedicated page for Artisan Acqu SEC filings (Ticker: PRENW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Artisan Acqu's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Artisan Acqu's regulatory disclosures and financial reporting.
Prenetics Global Ltd reported that Chief Financial Officer Lo Hoi Chun received a grant of 91,629 Restricted Stock Units (RSUs), each representing the right to receive one Class A ordinary share. These RSUs were granted under the company’s 2022 Share Incentive Plan as compensation.
The RSUs vest over time, with 7,635 RSUs vesting on May 19, 2026, 7,635.75 RSUs vesting on the 19th of each subsequent month through March 19, 2027 (total 76,358 shares), and 7,636 RSUs vesting on April 19, 2027. After this award, Lo Hoi Chun is reported as holding 597,930 RSUs.
Vested RSUs are not automatically converted into shares. Instead, settlement and delivery of Class A ordinary shares occur at Lo Hoi Chun’s election, in line with the company’s insider trading policy. This is a non-cash equity compensation grant, not an open-market share purchase or sale.
Prenetics Global Ltd reported that Chief Financial Officer Lo Hoi Chun received a grant of 91,629 Restricted Stock Units (RSUs), each representing the right to receive one Class A ordinary share. These RSUs were granted under the company’s 2022 Share Incentive Plan as compensation.
The RSUs vest over time, with 7,635 RSUs vesting on May 19, 2026, 7,635.75 RSUs vesting on the 19th of each subsequent month through March 19, 2027 (total 76,358 shares), and 7,636 RSUs vesting on April 19, 2027. After this award, Lo Hoi Chun is reported as holding 597,930 RSUs.
Vested RSUs are not automatically converted into shares. Instead, settlement and delivery of Class A ordinary shares occur at Lo Hoi Chun’s election, in line with the company’s insider trading policy. This is a non-cash equity compensation grant, not an open-market share purchase or sale.
Prenetics Global Limited, parent of premium health brand IM8, announced a multi-year global partnership with author and podcast host Jay Shetty, who becomes IM8’s Global Ambassador and a shareholder in Prenetics. This expands IM8’s reach beyond sport into Shetty’s large wellness-focused audience.
The announcement comes as IM8 raises its full-year 2026 revenue guidance to $190 million to $210 million after reporting preliminary Q1 2026 IM8 revenue of $33.8 million, nearly six times higher year over year. IM8’s May 2026 monthly revenue is tracking at about $15.5 million, implying roughly $186 million in annualized recurring revenue.
Prenetics Global Limited, parent of premium health brand IM8, announced a multi-year global partnership with author and podcast host Jay Shetty, who becomes IM8’s Global Ambassador and a shareholder in Prenetics. This expands IM8’s reach beyond sport into Shetty’s large wellness-focused audience.
The announcement comes as IM8 raises its full-year 2026 revenue guidance to $190 million to $210 million after reporting preliminary Q1 2026 IM8 revenue of $33.8 million, nearly six times higher year over year. IM8’s May 2026 monthly revenue is tracking at about $15.5 million, implying roughly $186 million in annualized recurring revenue.
Prenetics Global Limited, parent of premium health brand IM8, has appointed Brian J. Rosin as Chief Financial Officer of IM8. He brings nearly two decades of finance leadership in consumer e-commerce and wellness subscriptions and will report to CEO Danny Yeung.
The company highlights IM8 as one of the fastest-growing consumer health supplement brands, now sold in more than 40 countries and having surpassed $100 million in annualized recurring revenue within 11 months of launch. IM8 is projecting $190 million to $210 million in revenue for full year 2026, only its second year from launch, underscoring management’s expectations for rapid global expansion.
Prenetics Global Limited, parent of premium health brand IM8, has appointed Brian J. Rosin as Chief Financial Officer of IM8. He brings nearly two decades of finance leadership in consumer e-commerce and wellness subscriptions and will report to CEO Danny Yeung.
The company highlights IM8 as one of the fastest-growing consumer health supplement brands, now sold in more than 40 countries and having surpassed $100 million in annualized recurring revenue within 11 months of launch. IM8 is projecting $190 million to $210 million in revenue for full year 2026, only its second year from launch, underscoring management’s expectations for rapid global expansion.
Prenetics Global reported preliminary Q1 2026 revenue of $36.0 million, up sharply from $8.3 million a year earlier, driven by its IM8 premium nutrition brand. IM8 generated $33.8 million of revenue, compared with $5.7 million in Q1 2025, and improved gross margin to about 64%.
Company-wide gross profit was $23.3 million, with a loss from operations of $8.9 million and adjusted EBITDA loss of $5.6 million, showing the business is still investing for growth. Management now guides full-year 2026 IM8 revenue to $190–$210 million and expects Q2 2026 revenue of $46–$48 million, mostly from IM8.
Prenetics highlighted IM8’s subscription-led model, rising average order values, and expanding global footprint, with over 60% of IM8 revenue outside the U.S. The company remains debt-free and reported $56.0 million of cash at March 31, 2026, plus additional liquidity from divesting digital assets and investment funds, and has repurchased about $19 million of shares under a $40 million buyback program.
Prenetics Global reported preliminary Q1 2026 revenue of $36.0 million, up sharply from $8.3 million a year earlier, driven by its IM8 premium nutrition brand. IM8 generated $33.8 million of revenue, compared with $5.7 million in Q1 2025, and improved gross margin to about 64%.
Company-wide gross profit was $23.3 million, with a loss from operations of $8.9 million and adjusted EBITDA loss of $5.6 million, showing the business is still investing for growth. Management now guides full-year 2026 IM8 revenue to $190–$210 million and expects Q2 2026 revenue of $46–$48 million, mostly from IM8.
Prenetics highlighted IM8’s subscription-led model, rising average order values, and expanding global footprint, with over 60% of IM8 revenue outside the U.S. The company remains debt-free and reported $56.0 million of cash at March 31, 2026, plus additional liquidity from divesting digital assets and investment funds, and has repurchased about $19 million of shares under a $40 million buyback program.
Prenetics Global Limited announced that its IM8 brand has entered a multi-year partnership with Inter Miami CF, becoming the club’s exclusive Official Health Supplements Partner. The deal includes Inter Miami taking an equity stake in Prenetics, its first-ever equity position in a brand partner.
IM8 products such as Daily Ultimate Essentials, Daily Ultimate Longevity, and The Beckham Stack will be integrated into Inter Miami’s training facility for players and staff, supported by in-stadium branding and digital exposure. IM8 also receives group player name, image, and likeness rights for at least four players.
Since launching in December 2024, IM8 has surpassed $100 million in annualized recurring revenue, delivering more than 24 million servings across over 800,000 customer purchases in 40+ countries. The Company projects IM8 revenues of approximately $180 million to $200 million for full-year 2026.
Prenetics Global Limited announced that its IM8 brand has entered a multi-year partnership with Inter Miami CF, becoming the club’s exclusive Official Health Supplements Partner. The deal includes Inter Miami taking an equity stake in Prenetics, its first-ever equity position in a brand partner.
IM8 products such as Daily Ultimate Essentials, Daily Ultimate Longevity, and The Beckham Stack will be integrated into Inter Miami’s training facility for players and staff, supported by in-stadium branding and digital exposure. IM8 also receives group player name, image, and likeness rights for at least four players.
Since launching in December 2024, IM8 has surpassed $100 million in annualized recurring revenue, delivering more than 24 million servings across over 800,000 customer purchases in 40+ countries. The Company projects IM8 revenues of approximately $180 million to $200 million for full-year 2026.
Prenetics Global Limited plans to fully divest its treasury holdings of approximately 510 Bitcoin, targeting completion by May 14, 2026. Based on recent prices of about $80,000 per BTC, the company currently expects gross proceeds of roughly $40 million.
After the sale, Prenetics expects total cash, current financial assets and escrowed consideration to increase from about $112 million as of March 31, 2026 to approximately $145 million to $150 million, with no indebtedness. The Board has adopted a policy not to purchase Bitcoin or other digital assets going forward, focusing capital on the IM8 consumer health business, which is targeting $180 million to $200 million in FY2026 revenue.
The company intends to use divestment proceeds to potentially expand its up to $40 million share repurchase program, accelerate IM8 marketing, fund new product launches in Q4 2026 and support international expansion across more than 40 countries. Prenetics expects to report selected Q1 FY2026 results on May 14, 2026, when it also plans to disclose final Bitcoin sale proceeds and volume-weighted average price.
Prenetics Global Limited plans to fully divest its treasury holdings of approximately 510 Bitcoin, targeting completion by May 14, 2026. Based on recent prices of about $80,000 per BTC, the company currently expects gross proceeds of roughly $40 million.
After the sale, Prenetics expects total cash, current financial assets and escrowed consideration to increase from about $112 million as of March 31, 2026 to approximately $145 million to $150 million, with no indebtedness. The Board has adopted a policy not to purchase Bitcoin or other digital assets going forward, focusing capital on the IM8 consumer health business, which is targeting $180 million to $200 million in FY2026 revenue.
The company intends to use divestment proceeds to potentially expand its up to $40 million share repurchase program, accelerate IM8 marketing, fund new product launches in Q4 2026 and support international expansion across more than 40 countries. Prenetics expects to report selected Q1 FY2026 results on May 14, 2026, when it also plans to disclose final Bitcoin sale proceeds and volume-weighted average price.
Prenetics Global Ltd ownership update: Genetel Bioventures Ltd and Michael Yang Mengsu report beneficial ownership of 488,857 Class A Ordinary Shares, representing 3.3% of the Class A shares outstanding. The percentage is calculated on an aggregate of 14,697,463 Class A Ordinary Shares outstanding as of March 31, 2026.
The statement is filed by Genetel and Mr. Yang Mengsu and clarifies voting and dispositive powers shown on the cover page. Signatures on the amendment are dated April 22, 2025.
Prenetics Global Ltd ownership update: Genetel Bioventures Ltd and Michael Yang Mengsu report beneficial ownership of 488,857 Class A Ordinary Shares, representing 3.3% of the Class A shares outstanding. The percentage is calculated on an aggregate of 14,697,463 Class A Ordinary Shares outstanding as of March 31, 2026.
The statement is filed by Genetel and Mr. Yang Mengsu and clarifies voting and dispositive powers shown on the cover page. Signatures on the amendment are dated April 22, 2025.
Prenetics Global Limited announced a multi-year global partnership with NBA champion and two-time MVP Giannis Antetokounmpo, who becomes a global partner of IM8 and a shareholder in Prenetics. This aligns his 35 million-plus social followers with IM8’s growth strategy across the United States, Europe, Africa, and Asia.
IM8, co-founded with David Beckham, has rapidly scaled since its December 2024 launch, reaching $100 million in annualized recurring revenue in 11 months, more than 22 million servings delivered and about 750,000 customer purchases in 31 countries. The brand is projected to generate approximately $180–$200 million in revenue in 2026.
Management highlights strong alignment with athlete-partners, all of whom hold equity, and notes up to $42.75 million in combined corporate and personal share commitments. Prenetics reports approximately $160 million of adjusted liquidity and zero debt as of March 1, 2026, with adjusted EBITDA profitability targeted by Q4 2027.
Prenetics Global Limited announced a multi-year global partnership with NBA champion and two-time MVP Giannis Antetokounmpo, who becomes a global partner of IM8 and a shareholder in Prenetics. This aligns his 35 million-plus social followers with IM8’s growth strategy across the United States, Europe, Africa, and Asia.
IM8, co-founded with David Beckham, has rapidly scaled since its December 2024 launch, reaching $100 million in annualized recurring revenue in 11 months, more than 22 million servings delivered and about 750,000 customer purchases in 31 countries. The brand is projected to generate approximately $180–$200 million in revenue in 2026.
Management highlights strong alignment with athlete-partners, all of whom hold equity, and notes up to $42.75 million in combined corporate and personal share commitments. Prenetics reports approximately $160 million of adjusted liquidity and zero debt as of March 1, 2026, with adjusted EBITDA profitability targeted by Q4 2027.
Prenetics Global Ltd director Darshan Ravindra Shah filed an initial ownership statement showing equity interests in the company. He holds 5,599 Restricted Stock Units, each representing a right to receive one Class A Ordinary Share, which vest on February 15, 2027 under the 2022 Share Incentive Plan.
Following this filing, he also holds 4,506 Class A Ordinary Shares directly. The RSUs are scheduled to be settled and delivered in shares upon vesting, with the award expiring on February 16, 2032.
Prenetics Global Ltd director Darshan Ravindra Shah filed an initial ownership statement showing equity interests in the company. He holds 5,599 Restricted Stock Units, each representing a right to receive one Class A Ordinary Share, which vest on February 15, 2027 under the 2022 Share Incentive Plan.
Following this filing, he also holds 4,506 Class A Ordinary Shares directly. The RSUs are scheduled to be settled and delivered in shares upon vesting, with the award expiring on February 16, 2032.
Prenetics Global Ltd director and Chief Executive Officer Danny Sheng Wu Yeung has reported his initial ownership on a Form 3. He directly holds 933,380 Class B Ordinary Shares and 138,694 Class A Ordinary Shares. He also has indirect ownership of 647,592 Class B Ordinary Shares through Da Yeung Limited, a company he wholly owns.
Yeung additionally holds Restricted Stock Units representing 53,953 underlying Class B Ordinary Shares at an exercise price of $0.0001 per share, expiring on June 23, 2030. These RSUs were granted under the 2022 Share Incentive Plan and vest in scheduled tranches during 2026, with settlement of vested RSUs in Ordinary or Class A shares at his election.
Prenetics Global Ltd director and Chief Executive Officer Danny Sheng Wu Yeung has reported his initial ownership on a Form 3. He directly holds 933,380 Class B Ordinary Shares and 138,694 Class A Ordinary Shares. He also has indirect ownership of 647,592 Class B Ordinary Shares through Da Yeung Limited, a company he wholly owns.
Yeung additionally holds Restricted Stock Units representing 53,953 underlying Class B Ordinary Shares at an exercise price of $0.0001 per share, expiring on June 23, 2030. These RSUs were granted under the 2022 Share Incentive Plan and vest in scheduled tranches during 2026, with settlement of vested RSUs in Ordinary or Class A shares at his election.